Directory of Stock Market Company
This site is a directory of Stock Market Company in USA and Canada. Each company page contains a description, stock quote, news and much more. You have also access to the best stock market game on the web.
Search into NYSE and TSX
by quote, company name or key word
ALXA - Alexza Pharmaceuticals Inc
Alexza Pharmaceuticals, Inc. (Alexza), incorporated on December 19, 2000, is a pharmaceutical company focused on the research, development, and commercialization of products for the acute treatment of central nervous system (CNS) conditions. The Company’s product candidates are based on its technology, the Staccato system. The Staccato system vaporizes an excipient","NYSE, Nasdaq, S&P, trading, US market, Asian market, Dow Jones, FTSE, DJIA, DAX, stocks, bonds, shares","Connect to the most current information on stocks and bonds on Reuters.com. What you need to know now about NYSE, Dow Jones, S&P, and Nasdaq at Reuters.com"
Alexza Pharmaceuticals Inc News
Alexza Pharmaceuticals, Inc. (NASDAQ:ALXA) Investor Alert: Investigation over ...
Your-Story.org (press release) - May 16, 2012
Your-Story.org (press release) - May 16, 2012
An investigation on behalf of investors in Alexza Pharmaceuticals, Inc. (NASDAQ:ALXA) shares over potential securities laws violations by certain officers and directors at Alexza Pharmaceuticals, Inc. in connection with certain financial statements was ...
Hot Biotech Stocks Traded by Hedge Funds in First Quarter
TheStreet.com - May 16, 2012
TheStreet.com - May 16, 2012
By Adam Feuerstein 05/16/12 - 07:10 AM EDT BOSTON (TheStreet) -- Noteworthy hedge fund trading in biotech and drug stocks, culled from the 13F filings for the first quarter: [Hedge funds and mutual funds that manage more than $100 million are required ...
Alexza Reports 2012 First Quarter Financial Results and Provides Business Update
Sacramento Bee - May 11, 2012
Sacramento Bee - May 11, 2012
By Alexza Pharmaceuticals, Inc. MOUNTAIN VIEW, Calif., May 10, 2012 -- /PRNewswire/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today reported financial results for the fiscal quarter ended March 31, 2012 and provided a business update.
Biotech Industry Hotbed of Merger & Acquisition Speculation
MarketWatch (press release) - May 11, 2012
MarketWatch (press release) - May 11, 2012
NEW YORK, NY, May 11, 2012 (MARKETWIRE via COMTEX) -- In recent months the Biotech Industry has become a hotbed of Merger and Acquisition (M&A) activity and speculation.
Alexza Reports 2012 First Quarter Financial Results and Provides Business Update
MarketWatch (press release) - May 10, 2012
MarketWatch (press release) - May 10, 2012
MOUNTAIN VIEW, Calif., May 10, 2012 /PRNewswire via COMTEX/ -- Alexza Pharmaceuticals, Inc. (NASDAQ:ALXA) today reported financial results for the fiscal quarter ended March 31, 2012 and provided a business update.
ACCO, ADK, ALXA, AMCX, APEI, AGO are Releasing Earnings May-10
Fyxnews - May 10, 2012
Fyxnews - May 10, 2012
ACCO Brands Corp (ACCO) is releasing earnings Before Market Opens. ACCO Brands Corporation designs, develops, manufactures and markets a number of traditional and computer-related office products.
Alexza (NASDAQ:ALXA) New Drug Application unaccepted, AMN (NYSE:AHS) Reports ...
eStocksDaily - May 7, 2012
eStocksDaily - May 7, 2012
Alexza Pharmaceuticals, Inc. (NASDAQ:ALXA) announced on Friday its new drug application for Adasuve, a schizophrenic and bipolar disorder treatment, cannot be permitted by the US Food and Drug Administration until a deficiency at a manufacturing ...
Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Alexza ...
MarketWatch (press release) - May 7, 2012
MarketWatch (press release) - May 7, 2012
NEW YORK, May 7, 2012 /PRNewswire via COMTEX/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Alexza Pharmaceuticals Inc. ("Alexza Pharmaceuticals" or the ...
Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of Alexza Pharmaceuticals Inc
Reuters Key Development - May 7, 2012
Reuters Key Development - May 7, 2012
Most Worse Momentum at Healthcare Sector, Shares Plunges More Than 20%- SGYP ...
eStocksDaily - May 7, 2012
eStocksDaily - May 7, 2012
Shares of Synergy Pharmaceuticals (SGYP) go into the chasm, after the pharma's reported that it plans to offer 10 million common stock shares to finance its research and development activities, which comprise clinical trials of its plecanatide and ...
NYSE Media Coverage Selection of the best articles found in your favorit medias